Risk of venous thromboembolism amongst initiators of SGLT-2 inhibitors compared to other glucose-lowering agents

被引：0
|
作者：
Gopalakrishnan, Chandrasekar [1 ]
Desai, Rishi J. [1 ]
Kim, Seoyoung C. [1 ]
Patorno, Elisabetta [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
3982
引用
收藏
页码：591 / 592
页数：2
相关论文
共 50 条
  • [21] Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
    H. M. Colhoun
    S. J. Livingstone
    H. C. Looker
    A. D. Morris
    S. H. Wild
    R. S. Lindsay
    C. Reed
    P. T. Donnan
    B. Guthrie
    G. P. Leese
    J. McKnight
    D. W. M. Pearson
    E. Pearson
    J. R. Petrie
    S. Philip
    N. Sattar
    F. M. Sullivan
    P. McKeigue
    Diabetologia, 2012, 55 : 2929 - 2937
  • [22] Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics
    Lam, David
    Shaikh, Aisha
    KIDNEY360, 2021, 2 (04): : 742 - 746
  • [23] Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes, Rosalie A.
    van Baar, Michael J. B.
    Lytvyn, Yuliya
    Bjornstad, Petter
    Nieuwdorp, Max
    Cherney, David Z. I.
    van Raalte, Daniel H.
    DIABETES OBESITY & METABOLISM, 2019, 21 : 24 - 33
  • [24] Glucose-Lowering Effect of SGLT2 Inhibitors Varies among Seasons in Japanese Subjects with Type 2 Diabetes
    Wada, Yoshiharu
    Hamamoto, Yoshiyuki
    Fujikawa, Jun
    Honjo, Sachiko
    Abe, Megumi
    Okamura, Emi
    Hamasaki, Akihiro
    DIABETES, 2017, 66 : A459 - A459
  • [25] Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
    André J. Scheen
    Clinical Pharmacokinetics, 2014, 53 : 295 - 304
  • [26] Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
    Toshinobu Maki
    Sayaka Maeno
    Yasutaka Maeda
    Mayumi Yamato
    Noriyuki Sonoda
    Yoshihiro Ogawa
    Masanori Wakisaka
    Toyoshi Inoguchi
    Scientific Reports, 9
  • [27] The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes
    Stoian, Anca Pantea
    Sachinidis, Alexandros
    Stoica, Roxana Adriana
    Nikolic, Dragana
    Patti, Angelo Maria
    Rizvi, Ali A.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 109
  • [28] Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
    Maki, Toshinobu
    Maeno, Sayaka
    Maeda, Yasutaka
    Yamato, Mayumi
    Sonoda, Noriyuki
    Ogawa, Yoshihiro
    Wakisaka, Masanori
    Inoguchi, Toyoshi
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [29] HOSPITAL ADMISSION FOR COVID-19 AND USE OF DPP-4 INHIBITORS AS COMPARED TO OTHER GLUCOSE-LOWERING DRUGS
    Rodriguez-Martin, S.
    Rodriguez-Miguel, A.
    Lerma, V.
    Gil, M.
    Barreira-Hernandez, D.
    Carretero, A.
    de Abajo, F. J.
    GACETA SANITARIA, 2023, 37 : S78 - S79
  • [30] Drug-Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
    Scheen, Andre J.
    CLINICAL PHARMACOKINETICS, 2014, 53 (04) : 295 - 304
12345